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Abstract
The in vitro and in vivo characterization of an optimized formulation of nanoparticles (NPs)
loaded with a high content of dexamethasone palmitate (DEX-P), a chemotherapeutic adjuvant
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NPs are uniform in size and composition. Single photon emission computed tomography imaging
demonstrates significant tumor uptake of 111In-labeled DEX-P NPs in tumor-bearing mice. As
with many nanoparticle-based drug delivery systems, significant liver accumulation is observed.
Assessment of liver histology and blood tests show no apparent hepatic or renal toxicity of the
DEX-P NPs. Conversion of DEX-P to DEX occurs when DEX-P NPs are incubated with mouse
plasma, human tumor homogenate and ascites from tumor bearing mice, but not with human
plasma. This conversion is slower in plasma from Es1e(−/−)/SCID mice, a potential alternative
animal model that better mimics humans; however, plasma from these mice are not completely
devoid of esterase activity. The difference between blood and tumor esterase activity in humans
facilitates the delivery of DEX-P NPs to tumors and the release of dexamethasone by an esterase
trigger.
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1. Introduction
There is a large unmet need to improve the therapeutic efficacy of cancer chemotherapeutic
agents in solid tumors and to reduce their toxicities. One way this can be achieved is to
reduce physiological barriers in the microenvironment of the tumor and thereby facilitate the
uptake of these agents in tumors. Our previous studies demonstrated that the glucocorticoid
dexamethasone (DEX) acts to enhance the effectiveness and reduce the toxicity of
chemotherapeutic agents.[1,2] DEX appears to inhibit formation of high molecular weight
proteins in tumor interstitial fluid space; these proteins increase colloidal osmotic pressure
and thus elevate interstitial fluid pressure (IFP).[3-5] Tumor cells can often evade immune
responses by releasing chemokines and cytokines that alter immune cell function, but this is
more pronounced within the tumor microenvironment. This is typically observed in the form
of macrophages being transformed from phagocytic type cell to a cell that accumulates in
the tumor and releases proangiogenic and other molecules that facilitate tumor growth.
Corticosteroids reduce cellular synthesis of multiple inflammatory and angiogenic cytokines
such as vascular endothelial growth factor (VEGF), interleukin (IL)-1α, IL-1β, platelet
derived growth factor (PDGF), transforming growth factor-alpha (TGF-α), monocyte colony
stimulating factor (M-CSF aka CSF-1) and many others.[6-8] However, corticosteroids such
as DEX also induce side effects, most notably suppression of the adaptive immune response
due to depletion and inhibition of T cells.[9,10] Systemic delivery of DEX in cancer patients
may cause serious adverse effects resulting in increased infection rates, increased muscle
wasting, decreased albumin synthesis and increased insulin resistance in diabetics, thereby
limiting its application in the clinic.
To reduce DEX systemic toxicity and maximize the previously reported synergistic effect of
chemotherapy along with systemic DEX,[1,2] we have developed solid lipid nanoparticles
(NPs) containing the palmitate ester of DEX (DEX-P) for augmented tumor delivery. In
addition, DEX-P NPs as a chemotherapeutic adjuvant may improve the effectiveness of
multiple anticancer drugs. Instead of developing an individual carrying system for a single
anticancer drug, this pretreatment can be universal for improving the outcome of anticancer
therapy. [11] Increased circulation retention times can be accomplished by ‘pegylating’ NP
surfaces which reduces their interaction with circulating cellular elements and subsequent
removal by cells of the reticuloendothelial system. The NPs accumulate in tumor tissue due
to the enhanced permeability and retention (EPR) effect. Our previous in vitro studies
indicated that the release of DEX from NPs in the tumors is by an enzymatic trigger, i.e.,
esterases, which are present with high activity in tumors but with low activity in human
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plasma.[12,13] Carboxylesterases are over-expressed in tumor cells, and cell lysis can result
in significant activity of this enzyme in interstitial fluid. These enzymes can convert DEX-P
to DEX and subsequently release DEX at the tumor site which can then be taken up by
inflammatory and tumor cells known to have surface glucocorticoid receptors for DEX. [14]
Intact NPs containing DEX-P can also be taken up by phagocytes and tumor cells where the
DEX-P is converted to DEX by esterases within the cells. Therefore, it may be not necessary
to design NPs with tumor-specific targeting ligands on their surface. Our vision of the role
that DEX-P NPs administration will have on the tumor microenvironment is depicted in
Figure 1.
In this study, we attached 111In on the surface of DEX-P NPs in order to image the
biodistribution and tumor uptake of the NPs in vivo using single photon emission computed
tomography (SPECT). These images can be used to calculate the delivered dose and for
subsequent pharmacokinetic-pharmacodynamic modeling. The bioresponsive triggered
release of DEX from DEX-P NPs has great clinical potential, but several challenges remain
in the development and evaluation of such a system. The first is to prepare high payload NPs
of uniform composition and properties. We previously reported that some formulations can
lead to multiple populations of solid lipid nanoparticles where the drug payload in the
different NP populations was not uniform. [15] The second challenge is to develop a proper
animal model that can best mimic the human situation. High esterase activity in mouse
plasma rapidly converts the ester prodrug DEX-P to DEX which can then be released from
NPs. This is not expected to occur in human plasma due to its nominal esterase activity. The
purpose of this study was to characterize the optimized NP formulation with a high DEX-P
payload, track their tumor accumulation in vivo by imaging, and to determine if the
pharmacokinetic profile of radiolabeled NPs was different in carboxylesterase-deficient
athymic (Es1e(−/−)/SCID) mice compared to athymic nude (nu/nu) mice, which are
commonly used for human tumor xenograft and mimic humans for assessing anti-tumor
efficacy in vivo.
2. Results and Discussion
2.1. Preparation of Radiolabeled High Payload DEX-P Nanoparticles
To increase the potency of nanoparticle-based drugs and reduce the potential side effects
caused by the components of the nanocarriers, a high payload NP formulation is critical. In
our previous study, when nanoparticles with a lipid to drug ratio of 10:1 (w/w) were
prepared, two populations of nanoparticles with differing drug content were identified by gel
filtration chromatography (GFC).15 Thus, a new formulation was developed by substituting
a portion of the lipid component with DEX-P so that the final lipid to drug (strearyl alcohol
to DEX-P) ratio was 1:1 (w/w), with equivalent lipid to active drug (DEX) ratio of 1: 0.6.
The mean particle size of these nanoparticles was 108.3 ± 1.3 nm with a narrow size
distribution based on signal intensity by dynamic light scattering (polydispersity index =
0.146 ± 0.030). The addition of DMPE-DTPA to the formulation resulted in nanoparticles
(DTPA-NPs) with a slightly larger particle size (115.0 ± 0.9 nm; polydispersity index =
0.172 ± 0.009). While measurement of intensity-based size distribution by dynamic light
scattering is commonly reported for characterization of nanoparticles, this may be
misleading if the system is heterogeneous. A new technology called nanoparticle tracking
analysis was used to measure the number-based size distribution of these nanoparticles and
revealed that the majority of our nanoparticles had a diameter of ~ 95 nm with a smaller
population of particles of ~ 180 nm in diameter (Figure 2A). After passing [3H]-DEX-P /
[14C]-stearyl alcohol (SA) nanoparticle preparation through a 0.2 μm filter, the recovery of
radioactivity in the filtrate was 94.0% and 96.5% for 3H and 14C, respectively. The
encapsulation efficiency of [3H]-DEX-P was determined to be 91.7% after purification by
ultrafiltration. The active drug loading (DEX to total NP mass) was calculated to be 6%
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based on the encapsulation efficiency, assuming no loss of other ingredients during the
purification. In parallel, after passing through a 0.2 μm filter, the nanoparticle suspension
was loaded onto a GFC column. The GFC profile of DTPA-NPs without radioactive metals
bound to their surface yielded a single peak containing both DEX-P and SA, indicating that
there was only one population of nanoparticles in the suspension (Figure 2B).
Radionuclides such as 111In can be attached to nanoparticles by chelation with DTPA
moieties and used for tracking the nanoparticles in vivo by noninvasive imaging. 111In
decays by electron capture and the distribution of 111In-labeled NPs in animals can be
imaged by SPECT. It has relatively long half-life (2.8 days), which is an advantage when
tracking nanoparticle biodistribution is required for more than 24 h. After chelation of the
radioactive metals by DTPA on the surface of NPs, ultrafiltration was used to remove the
unchelated metals. The recovery of the radioactivity from ultrafiltration was about 98%,
indicating minimal membrane binding of the radiolabel. The GFC of purified [3H]-DEX-P/
[14C]-SA/[111In]-DTPA-NPs ([3H/14C/111In]-NPs) showed that all three of these
radionuclides were detected in a single peak indicating a mono-distribution particle size and
composition of these nanoparticles (Figure 2C).
2.2. Conversion of DEX-P to DEX in Various Media
The rate at which NP-associated DEX-P is converted to DEX after incubation in various
media is shown in Figure 3. In plasma from nu/nu mice, the conversion of DEX-P to DEX
occurred immediately after incubation and was nearly 90% complete after 3 hours. [3H]-
DEX conversion was also observed when the [3H]-DEX-P NPs were incubated with a
carboxylesterase solution (10 mg/mL), but the initial rate was slower than observed in nu/nu
mouse plasma. When the NPs were incubated in human plasma, the conversion of [3H]-
DEX showed no significant difference from that in PBS (p > 0.05), while incubation in
plasma from esterase-deficient mice showed significantly less conversion (p < 0.05) of [3H]-
DEX than observed in nu/nu mouse plasma. Modification of the NP formulation produced
little effect on the esterolysis of DEX-P. It is expected that DEX-P will be stabilized in NPs
in circulation in humans but not in mice. Both human tumor homogenate and tumor cell
lysate exhibited high esterase activity as shown in our previous study.[12] Esterases are
mainly expressed intracellularly by tumor cells and inflammatory cells, but tumor interstitial
fluid may also have a high esterase content due to leakage from intact or damaged cells
coupled with a defective drainage system to remove them from the interstitial space. Ascites
due to cancer may reflect the properties of interstitial fluid. The conversation of DEX-P to
DEX was tested in ascites from mice bearing human ovarian tumor. As shown in Figure 3,
the conversation in ascites was comparably high to mouse plasma and esterase solution at
each time point, which indicated that the drug may be released from NPs at both the intra-
and inter- cellular level.
2.3. Tumor Cell Uptake
The uptake of nanoparticle-based DEX-P by tumor cells was 15 times greater than the
uptake of free DEX-P after a 1 h incubation (Figure 4), although the uptake of the latter
increased slightly after a 4 h incubation. However, there was no significant difference (p >
0.05) in the tumor cell uptake between the 1 h and 4 h incubation times for DEX-P NPs.
Thus, it appears that nanocarriers may enhance the delivery of drug to the cells through
internalization but may not affect uptake of free drugs by a diffusion mechanism.
2.4. SPECT/CT Imaging of 111In-NPs
Non-invasive micro-SPECT imaging allows tracking of radiolabeled nanoparticles at
different time points in the same animal after administration of radiolabeled NPs to avoid
variation between animals. The distribution of the radioactivity in the animal can be related
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to anatomy by combining SPECT with computed tomography (CT). DMPE-DTPA, a
phosphate ester lipid-based DTPA chelator was used to chelate 111In for micro-SPECT/CT
imaging. Because DEX-P exhibited varying stability in plasma from various species, it
appears that the usual mouse models are inadequate predictors of ester prodrug stability in
humans. We were interested to learn if this phenomenon was also observed for other ester-
linked compounds such as DMPE-DTPA. Therefore, [111In]-DTPA was mixed with mouse
plasma to determine if this radiolabel was bound by plasma protein. The recovery of 111In
from the ultrafiltrate was >90% indicating that 111In remained bound to DTPA. The
measured release of [111In]-DTPA from the [111In]-DTPA-NPs at 2 and 24 h time points
was 1.1 ± 0.1% and 14.5 ± 0.7%, respectively, which was much slower than the release of
[3H]-DEX-P from NPs as previously reported.[12] DMPE-DTPA has two ester bonds and
only when both are cleaved will the DTPA-metal complex be released from NPs. It is also
possible that the ester bonds of DMPE-DTPA are more embedded within the NPs and are
not readily accessible to the plasma esterases. The results indicated that DMPE-DTPA
would not be rapidly hydrolyzed in the circulation even though DMPE and DTPA are linked
by an ester bond, similar to DEX-P. In humans, the stability of the chelator is not expected
to be an issue. Therefore, [111In]-DTPA-NPs were used for the initial micro-SPECT/CT
imaging study to determine the NP biodistribution in tumor-bearing nu/nu mice. A small
molecule complex, [111In]-DTPA, was administered intravenously as a control. Significant
tumor as well as liver uptake was observed 5 h and 24 h after dosing [111In]-DTPA NPs
(Figure 5B and 5C). This is particularly evident in the 3D volume rendering image from the
5 h time point (Figure 5D). Residual whole body radioactivity in these animals was as high
as 55% after 24 h which indicated that the NPs have a long retention time (Figure 5E). In
contrast, there was no tumor uptake and very little residual radioactivity in the whole animal
5 h after administration of [111In]-DTPA (Figure 5A and 5E). These results are consistent
with the in vitro study on the stability of ester bond of [111In]-DTPA-NPs in mouse plasma.
Tumor and liver uptake of the [111In]-DTPA-NPs was quantified from SPECT images.
Tissue uptake of radioactivity based on region of interest (ROI) analysis was 1230.2 and
3533.8 counts/mm3 in tumor and liver, respectively at the 5 h time point, and both decreased
after 24 h (485.6 and 1155.6 counts/mm3 in tumor and liver, respectively, decay corrected).
The intensity ratio of tumor to liver radioactivity signal from the images increased from 0.35
to 0.42 from the 5 h to the 24 h time point. The significant accumulation of the [111In]-
DTPA-NPs in the tumor as seen in the SPECT images indicated that this nanocarrier is
capable of delivering DEX-P to tumors and that the concentration of DEX in the tumors can
be quantified. [111In]-DTPA NPs without DEX-P were also injected to tumor bearing mice
to investigate the effect of the drug on the biodistribution. Tissues were collected at 24 h
post injection.
2.5. Assessment of Toxicity
Significant liver accumulation of NPs was observed from SPECT images. To test the liver
toxicity following administration of a single i.v. dose of DEX-P NPs containing 0.15 mg
(the same dose as other in vivo studies) of DEX-P to tumor bearing mice, liver histology and
blood tests were performed and compared to a saline control group. It appeared from the
SPECT images that liver uptake was greatest 5 h after the administration compared to 2 h
and 24 h time points (data was not shown). Thus, the 5 h and one week time points were
chosen to study acute and delayed toxicity of the nanoparticles. Liver and kidney function
were analyzed based on plasma tests including albumin (Alb), alanine transaminase (ALT),
aspartate transaminase (AST), alkaline phosphatase (ALP), lactate dehydrogenase (LDH),
gamma glutamyl transpeptidase (GGT) and blood urea nitrogen (BUN). No liver toxicity
was identified 5 h and 1 week after the treatment based on liver histology. Mild-to-moderate
vacuolation of convoluted tubules was observed in kidneys from both control and treatment
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groups, but the BUN test indicated normal renal function. Table 1 shows that the AST, ALT
and LDH levels increased 5 h after dosing DEX-P NPs in keeping with the known transient
effect of glucocorticoids on hepatic enzymes.[16] However, no significant difference was
found between the treatment group the control groups 1 week after administration (p >
0.05). For Alb, ALP, and GGT levels, no significant difference was observed between the
treatment groups and the control group at both the 5 h and 24 h time points (p > 0.05). The
results demonstrated that administration of DEX-P NPs did not result in liver or kidney
toxicity despite high liver uptake.
2.6. Pharmacokinetics (PK) of NP-based DEX and 111In-NPs
Due to the high esterase activity in mouse plasma, the nu/nu mouse may not be an
appropriate animal model to mimic humans.12,13 Es1e(−/−)/SCID mouse model was used to
determine if its reduced serum esterase activity, as demonstrated in the in vitro studies
described above, affected the PK of NP-based DEX-P. The PK of [3H]- DEX-P NP in nu/nu
and Es1e(−/−)/SCID mice, determined by tracking the radioactivity in blood, showed
significant differences at early time points up to 3 h. The % of the injected dose per gram
(%ID/g) of blood for the nu/nu mice were 4.43 ± 0.82, 1.49 ± 0.21 and 1.12 ± 0.23 at the 10
min, 30 min and 1 h time points, respectively, while the corresponding values for the
Es1e(−/−)/SCID mice were 7.64 ± 0.33, 2.58 ± 0.21, 1.86 ± 0.28. However, the Es1e(−/−)/
SCID mice apparently are not completely devoid of esterase activity, and enzymes other
than carboxylesterase may cleave DEX-P as well. The free DEX released from the NPs is
expected to be rapidly removed from the circulation. The PK curves of the two animal
models were superimposable after 3 h. Furthermore, as shown in Figure 6, blood
concentration of NPs in nu/nu mice as indicated by 111In was significantly higher than blood
concentration of [3H]- DEX-P in nu/nu or Es1e(−/−)/SCID mice (p < 0.05). This supported
the speculation that the residual esterase activity in Es1e(−/−)/SCID mouse plasma alters the
biodistribution profile of the ester prodrug. However, this would not be the case in human
plasma. The in vitro release data suggested that in humans the drug will be stabilized in the
nanoparticles in circulation but will release DEX at the tumor site due to the local high
esterase activity. Enhanced tumor delivery of nanoparticles was demonstrated by SPECT
imaging. All the evidence suggested that DEX-P NP will enhance the delivery of DEX to
tumors, while an appropriate animal model is needed to directly demonstrate this enhanced
delivery to tumors.
3. Conclusions
High payload nanoparticles containing a DEX ester prodrug, DEX palmitate, and an
imaging agent, lipid DTPA chelated 111In, were developed for delivering DEX specifically
to tumors and tracking nanoparticles by SPECT. These dual therapeutic-imaging NPs were
of uniform size and composition. Enzymatically-catalyzed esterolysis resulted in the release
of DEX from the nanoparticles. Mouse models may not be appropriate for in vivo studies of
ester prodrugs due to the high esterase activity in mouse plasma which was not observed in
human plasma. High esterase activity in human tumors facilitates the triggered release of
DEX specifically in tumors. The release can be in tumor cells, inflammatory cells or tumor
interstitial space. SPECT/CT images showed significant tumor accumulation of NPs 5 h
after intravenous administration of the [111In]-DEX-P NPs to nu/nu mice bearing human
lung cancer A549 tumors. Liver uptake dominates the tissue distribution of drug loaded NPs.
However, no liver toxicity was observed based on liver histology and liver function tests.
The DEX-P ester was hydrolyzed slower in plasma from Es1e(−/−)/SCID mice. Blood
concentrations of radioactivity were 2-fold higher in these mice within 3 h after i.v. injection
of radiolabeled DEX-P NPs than in nu/nu mice. However, Es1e(−/−)/SCID mice apparently
are not completely devoid of esterase activity. This residual esterase activity may alter the
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biodistribution profile of the ester prodrug and, as a result, the PK profile of the tritium-
labeled compounds is significantly different from that of 111In-NPs. Further efforts are being
made to develop an appropriate animal model that can demonstrate the efficacy of
nanoparticle-based DEX-P delivery and bioresponsive release of DEX in tumor tissues. The
use of a nanoparticle-based chemotherapeutic adjuvant for making the tumor
microenvironment more favorable for anti-cancer drugs and thus improving the therapeutic
indices of multiple therapeutic agents should be readily translatable to the clinic.
Radiolabeled drug-containing NPs may be used in image guided drug delivery and be




Tritiated dexamethasone ([6,7-3H(N)]; [3H]-DEX, specific activity = 35-50 Ci/mmol)
and 14C-stearyl alcohol ([1-14C]; [14C]-SA, specific activity = 50-60 mCi/mmol) were
purchased from American Radiolabeled Chemicals Inc. (St. Louis, MO, USA). 111InCl3 in
HCl was purchased from PerkinElmer (Waltham, MA, specific activity 380-415 Ci/mmol).
Dexamethasone (DEX) and bovine liver esterase were purchased from Sigma (St. Louis,
MO, USA). Stearyl alcohol (SA) was obtained from Spectrum Chemical (Gardena, CA,
USA). Brij®78 and polysorbate 60 were provided by Croda Inc. (Edison, NJ, USA).
Polyethylene glycol 6000 monostearate (PEG6000MS) was a gift from Hallstar (Chicago,
IL, USA). 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-N-
diethylenetriaminepentaacetic acid (DMPE-DTPA) was purchased from Avanti Polar Lipids
(Alabaster, AL, USA). Sepharose CL-2B was obtained from GE Healthcare (Piscataway,
NJ, USA). All other chemicals were of reagent grade and used without further purification.
Preparation of high payload DEX-P nanoparticles
All NPs were prepared using the ‘nanotemplate engineering’ technique. The procedures to
synthesize radiolabeled DEX-P ([3H]-DEX-P) and prepare DEX-P NPs have been
previously described.12,13 The formulation was improved by replacing a portion of the lipid
with DEX-P to achieve a high drug/lipid mass ratio of unity. The chelating reagent, DMPE-
DTPA was incorporated into the NPs for the purpose of attaching radionuclides to the
surface of the nanoparticles. Briefly, solid lipid nanoparticles were derived from a
microemulsion comprised of [3H]-DEX-P and non-labeled DEX-P (1 mg/mL), [14C]-SA
and non-labeled SA (1 mg/mL), polysorbate 60 (0.5 mg/mL), Brij®78 (3.5 mg/mL),
PEG6000MS (3.5 mg/mL) and DMPE-DTPA (0.1 mg/mL). Addition of warm DI water (pH
7.4, 70°C) to the melted mixture of oil, drug and surfactants yielded a microemulsion. After
stirring in a 70°C water bath for 1 h, the warm microemulsion was cooled to 25°C resulting
in the formation of NPs (or DTPA-NPs) containing [3H]-DEX-P and [14C]-SA. The
nanoparticle suspension was purified using a 0.2 μm filter to remove large particles and an
ultrafilter (MWCO 50 kD) to remove free surfactants, DMPE-DTPA and drug. The retentate
was washed 4 times and resuspended in 0.15 M ammonium acetate buffer (pH 5.0). The
amounts of [3H]-DEX-P and [14C]-SA in the NPs were quantified using a Tri-Carb 3110TR
Liquid Scintillation Counter (LSC; PerkinElmer, Waltham, MA, USA).
For the preparation of radiolabeled NPs, a neat solution of 111InCl3 was added to the
DTPANP suspension and stirred at 300 rpm for 1 h at room temperature. These NPs were
purified by ultrafiltration (MWCO 50 kD) after washing three times with saline.
Radioactivity from these photon-emitting radionuclides in each filtrate was quantified with a
Wizard2 Automatic Gamma Counter (PerkinElmer, Waltham, MA, USA) using the 173 and
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247 keV energy windows associated with the decay of 111In. [111In]-DTPA-NPs without
radiolabeled SA and DEX-P were prepared for in vivo SPECT/CT imaging.
Characterization of the prepared DEX-P NPs
Particle size distributions of the formed NP suspensions based on intensity from dynamic
light scattering were measured using a Zetasizer Nano ZS (Malvern, Worcestershire, UK).
Particle size number distribution was measured by nanoparticle tracking analysis using a
NanoSight LM10 system (Nanosight, Wiltshire, UK). Gel filtration chromatography (GFC)
of NPs or [111In]-DTPA-NPs containing [3H]-DEX-P and [14C]-SA was performed by using
a 100 × 10 mm column packed with Sepharose CL-2B (bed volume = 8 mL). Two hundred
microliters of [3H/14C]-NPs were applied to a pre-equilibrated column and eluted with
phosphate buffered saline (PBS, pH 7.4) at a flow rate of 30 mL/h. Fractions (1 mL) were
collected, and radioactivity in 100 μL aliquots of each fraction was quantified by mixing
with 5 mL of liquid scintillation cocktail and counting using the LSC. The corrected specific
activities of [3H]-DEX-P and [14C]-SA were calculated by dividing radioactivity by total
mass. The mass of DEX-P and SA in each fraction was calculated by dividing the amount of
radioactivity in the fraction by the corrected specific activity.
Conversion of DEX-P to DEX
Thin layer chromatography (TLC) was used to quantify the cleavage of DEX-P to DEX in
various media. Briefly, 2 μL of [3H]-DEX-P solution in DMSO or 2 μL of the [3H/14C]-NP
suspension were added to 18 μL of nu/nu mouse plasma, Es1e(−/−)/SCID mouse plasma,
human plasma, ascites fluid or a 10 mg/mL in PBS esterase solution (n = 3). A mixture of
[3H]-DEX-P and plasma or enzyme solution was incubated at 37°C. At t = 0, 1, 3, 6 and 24
h, 2 μL of the mixture were collected and mixed with 10 μL of acetonitrile. The mixture was
centrifuged at 10,000 g for 10 min. The entire supernatant was loaded onto a silica TLC
plate and developed using a mobile phase consisting of chloroform and ethyl acetate (7:3, v/
v). After completion of TLC separation, each plate was cut into two sections. The section
with Rf = 0 - 0.2 was recorded as ‘bottom’ (indicating DEX), while the other section of the
TLC plate was recorded as ‘top’ (indicating DEX-P). The top and bottom sections of the
TLC plates were solubilized with 1 mL of SolvableTM followed by the addition of
scintillation cocktail. The radioactivity of each sample was quantified by liquid scintillation
counting. All experiments were performed in triplicate.
Tumor Cell Uptake
Human lung epithelial carcinoma A549 cells were employed to study the tumor uptake of
nanoparticles. A549 cells were purchased from the American Type Culture Collection
(Manassas, VA) and cultured in DMEM with 2 mM L-glutamine, antibiotics, and 10% FBS
at 37°C in a humidified atmosphere with 5% CO2. The cultured cells were seeded in a 24-
well plate at a density of 1 × 105 cells/well with 1 mL of growth media and incubated at
37°C under 5% CO2 for 24 h. Cell numbers were adjusted so that each well contained
approximately 2 × 105 cells. After removing the cell culture media, 1 mL of serum-free
media containing the radiolabeled nanoparticles or [3H]-DEX-P solution was added to each
well. [3H]-DEX-P solution served as a control and the concentration of DEX-P was adjusted
to be the same as that in the nanoparticles. Due to its low solubility, DEX-P was dissolved in
DMSO and then diluted 10 times using culture media. Following incubation periods of 1 and
4 h, the cells were washed and rinsed with PBS to remove the non-internalized radiolabels.
To each well, 300 μL of cell lysis buffer was added and the cells were subsequently
incubated and mixed for 10 min on a rocker. A 200 μL aliquot of the cell lysate was
analyzed by liquid scintillation counting and the remainder (~100 μL) was saved to
determine the protein concentration by the bicinchoninic acid (BCA) assay.
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Animal Xenograft Tumor Model
Female nu/nu mice (20–25 g; Charles River Laboratories, Wilmington, MA) and female
Es1e(−/−)/SCID mice ( 22-28g) developed at the St. Jude Children’s Research Hospital
(Memphis, TN) were handled following the guidelines of an approved protocol by the
University of North Carolina Institutional Animal Care and Use Committee in accordance
with the NIH Guidelines. Human non-small cell lung epithelial carcinoma A549 cells were
allowed to grow to 70% confluence and resuspended in DMEM medium after incubation
with trypsin. Mice were injected with A549 cells (2 × 106 cells/100 μL/mouse)
subcutaneously on the right flank. The tumors were measured by calipers twice per week
and the tumor volume was calculated.
In vivo imaging study
Imaging of the biodistribution of [111In]-DTPA NPs was conducted using a small animal
SPECT/CT imaging system (eXplore speCZT/CT-120, GE Healthcare Inc., Waukesha, WI,
USA). Female nu/nu mice bearing human lung carcinoma A549 xenografts were
administered [111In]-DTPA or [111In]-DTPA-NPs containing DEX-P via tail vein (n=6).
Each mouse was administered approximately 0.5 mCi of 111In in 150 μL of either saline (for
[111In]-DTPA) or NP suspension containing 0.15 mg of DEX-P. At various time points, the
amount of radioactivity retained in the whole body of the mouse was measured using an
ionization chamber/dose calibrator (Model CRC-15R, Capintec Inc., Ramsey, NJ, USA).
SPECT/CT images were acquired at 5 and 24 h after administration of the radiolabel.
Anatomical CT imaging was performed initially followed by SPECT imaging in which
images were acquired using a mouse slit collimator providing 1.5 mm transaxial resolution
and 2.5 mm axial resolution. he SPECT and CT images were co-registered and the liver and
tumor volumes were manually segmented based on CT images. The average radioactivity
counts of each voxel (0.4×0.4×2.46 mm3) in liver and tumor tissues of the SPECT images
were measured using MicroView software on reconstructed tomographic images.
Toxicity assessments
Tumor bearing mice were injected via tail vein with either nanoparticles containing
dexamethasone (150 μL of NP suspension containing 0.15 mg DEX-P) or saline as control
(n=4). Blood, liver, kidney and spleen were collected at 5 h and 1 week after the injection.
Liver and kidney function were analyzed based on plasma tests including albumin (Alb),
alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP),
lactate dehydrogenase (LDH), gamma glutamyl transpeptidase (GGT) and blood urea
nitrogen (BUN). Liver, kidney and spleen tissues were fixed by 10% formalin and
embedded in paraffin. Tissue slices were subjected to hematoxylin and eosin (H&E)
staining.
Pharmacokinetics of DEX-P and 111In-NPs
The PK of 111In-NPs and NP-based [3H]-DEX-P was studied in nu/nu and Es1e(−/−)/SCID
mice bearing A549 tumors by obtaining blood samples at 15 min, 30 min, 1 , 3 , 6 and 24 h
after administration and calculating % ID/g blood after measuring the radioactivity and the
mass of the blood (n=6 for nu/nu mice groups and n=3 for Es1e(−/−)/SCID due to the limited
number of these mice available).
Statistical analysis
Data are presented as mean ± standard deviation. Groups were compared using analysis of
variance (ANOVA) one-way test with SigmaStat 3.5 software (Systat Inc., San Jose, CA).
Differences were considered statistically significant when p < 0.05, and the Holm-Sidak
Kim et al. Page 9













method was used to perform pairwise multiple comparisons on significant effects and
interactions.
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Theoretical model depicting the role of DEX-P NPs in blocking immune and cytokine
related effects in the tumor and normal tissues. DEX will be released intra-and inter-
cellularly and be taken up by phagocytes and tumor cells.
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Number-based particle size distribution determined by nanoparticle tracking analysis (A)
and GPC profiles of [3H]-DEX-P loaded [14C]-NPs (B) and [3H/14C/111In]-NPs (C)
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Conversion rate of NP associated DEX-P to DEX in various media
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Uptake of DEX-P by A549 lung cancer cells after 1 h and 4 h incubation. [3H]-DEX-P was
used to quantify the mass of DEX-P in the cells. Cell protein concentration was determined
by the BCA assay.
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SPECT/CT images of tumor bearing mice. A,B and C are coronal SPECT/CT images 5 h
after administration of 111In-DTPA as well as 5 h and 24 h after administration of 111In-
NPs. The gray outline of the animal is seen in the CT image while the colored areas are the
co-registered SPECT image of the 111In distribution. A 3D volume rendering image is
shown in D. These images show that the radioactivity associated with 111In-NPs
accumulates in the tumor region (along with significant liver accumulation) while
radioactivity associated with 111In-DTPA does not. E shows the whole body retention of
radioactivity following administration of 111In-NPs and 111In-DTPA.
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Pharmacokinetics (% of the injected dose per gram (%ID/g) vs. time) of [3H]- DEX-P NPs
and 111In-NPs in nu/nu and Es1e(−/−)/SCID mice
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Table 1















Control 25.0± 7.1 36.7 ± 4.6 1.8 ± 0.1 74.0 ± 7.1 66.0 ± 7.1 776.0 ± 80.6 6.0 ± 0
5 h 23.0 ± 2.8 48.0 ± 3.7 2.4 ± 0.1 216.0 ± 101.7 71.2 ± 3.8 3243.5±2293.2 4.0±1.6
1 week 23.0±2.2 36.2 ± 3.1 2.1 ± 0.2 72.3 ± 8.5 68.5 ± 5.3 699.0 ± 63.0 5.5 ± 1.0
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